MedTrace Logo

Total Intravenous Anesthesia and Recurrence Free Survival

NCT04513808 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1614

Last updated 2024-12-04

No results posted yet for this study

Summary

The investigators propose to compare recurrence-free survival in patients having potentially curative (Stages 1-3) surgery for esophageal cancer who will be randomly assigned to propofol-based total intravenous anesthesia or sevoflurane-based balanced general anesthesia.

Conditions

  • Esophageal Cancer

Interventions

DRUG

Propofol-based total intravenous anesthesia

Propofol-based total intravenous anesthesia, titrated to clinical need.

DRUG

Sevoflurane intravenous anesthesia

Sevoflurane intravenous anesthesia, titrated to clinical need.

Sponsors & Collaborators

  • The Cleveland Clinic

    lead OTHER

Principal Investigators

  • Yuwei Oui, MD · Shahai Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-15
Primary Completion
2025-12-31
Completion
2027-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04513808 on ClinicalTrials.gov